Sandoz Inc. v. Amgen Inc.: Supreme Court Clarifies BPCIA Provisions








On June 12, 2017, the United States Supreme Court issued its first ruling on two key provisions of the Biologics Price Competition and Innovation Act (“BPCIA”) concerning the resolution of patent infringement suits in connection with the submission to the Food and Drug Administration (“FDA”) of applications to commercialize biosimilars in the United States.1

To view the entire article please visit here.

0 views0 comments

Recent Posts

See All